| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Oncogenic activation (e.g. amplification) of uman epidermal growth factor receptor 2 (HER2) results in its protein overexpression and subsequent abnormal cell signalling, which contributes to cancer progression. Important issues for HER2-targeted therapy in GC are inaccurate assessments of HER2 status owing to intratumoral heterogeneity, which results in inappropriately choosing patients for HER2-targeted therapy. We investigated the potential clinical utility of the droplet digital PCR (ddPCR)-based HER2 copy number (CN) as a marker for the temporal and/or spatial heterogeneities of GC during treatment progress. The plasma HER2 amplification determined by ddPCR is a repeatable and noninvasive approach for real- time evaluations of the HER2 status to monitor the effects of treatments for patients with HER2-positive GC and enable treatment options for patients with HER2-negative GC but positive conversion of the HER2 status after recurrence.
|
